Full Press Release Details
Receives 3 Million NIS Grant
Israel's Office of the Chief Scientist
Ticker Symbol: U:BCLI
NEW YORK & PETACH TIKVAH, Israel -- (Business Wire) --
BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading
developer of adult stem cell technologies for neurodegenerative diseases, announced today that Brainstorm Cell Therapeutics Ltd.
was awarded a 3 million NIS grant from Israel's Office of the Chief Scientist (OCS) for the year 2013. The grant is intended
to support BrainStorm's Research and Development program for its innovative stem cell therapy candidate NurOwn.
"We are thankful to the OCS for its continued support
of our Research and Development program. The non-dilutive capital funding from the OCS will help facilitate continuation of our
clinical trials in Israel, as well as our preparations for clinical trials in the USA," said Dr. Adrian Harel, BrainStorm's
The OCS has supported BrainStorm Cell Therapeutics Ltd. since
2007, providing grants of a total of $1.8 million until today. The Company is required to pay royalties to the OCS, amounting to
3% - 3.5% of revenues derived from sales of the products funded with these grants, but only up to the amount equal to 100% of the
grants received plus LIBOR interest.
As reported by Brainstorm on Monday December 10, the Company
anticipates announcing a new date for its shareholders teleconference shortly.
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company
engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment
of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive,
worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the
company's website at www.brainstorm-cell.com.
About the Office of the Chief Scientist
The Office of the Chief Scientist (OCS) in Israel's Ministry
of Industry, Trade and Labor is charged with execution of government policy for support of industrial R&D. The goal of the
OCS is to assist in the development of technology in Israel as a means of fostering economic growth, encouraging technological
innovation and entrepreneurship, leveraging Israel's scientific potential, enhancing the knowledge base of industry in Israel,
stimulating high value-added R&D and encouraging R&D collaboration both nationally and internationally.
Safe Harbor Statement
Statements in this announcement other than historical data
and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm
Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms
and phrases such as "may", "should", "would", "could", "will", "expect",
"likely", "believe", "plan", "estimate", "predict", "potential",and
similar terms and phrases are intended to identify these forward-looking statements.The potential risks and uncertainties include,
without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence
on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific
consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form
10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.These factors should be considered carefully, and readers
should not place undue reliance on BrainStorm's forward-looking statements.The forward-looking statements contained in this
press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not
assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's
beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected
in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
BrainStorm Cell Therapeutics Inc.
Dr. Adrian Harel, Ph.D., CEO